The popularity of Sildenafil initially fueled a surge for major pharmaceutical companies, but recent shifts present a murky outlook for investors. Generic versions are eating into revenue, and ongoing patent challenges https://deaconaqef422391.fitnell.com/82248342/viagra-and-big-pharma-a-precarious-play